Oracort and Pulmicort drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Oracort (triamcinolone acetonide) and Pulmicort (budesonide). Common drug interactions include macular degeneration among females.

The phase IV clinical study analyzes what interactions people have when they take Oracort and Pulmicort. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Oracort?

Oracort has active ingredients of triamcinolone acetonide. eHealthMe is studying from 175 Oracort users. Check the latest studies of Oracort.

What is Pulmicort?

Pulmicort has active ingredients of budesonide. It is often used in asthma. eHealthMe is studying from 34,980 Pulmicort users. Check the latest studies of Pulmicort.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

15 people who take Oracort and Pulmicort together, and have interactions are studied.

Oracort and Pulmicort drug interactions.

What are the common drug interactions of Oracort and Pulmicort, by gender? *:

female:

Macular degeneration (painless eye condition that leads to the gradual loss of central vision)
Drug ineffective
Thirst
Weight decreased
Activities of daily living impaired
Dyspnoea (difficult or laboured respiration)
Ear infection
Finger deformity (a deformed position of the finger)
Blood pressure increased
Heart rate increased

male:

n/a

What are the common drug interactions of Oracort and Pulmicort, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Blood sodium decreased
Joint swelling
Pneumonia
Pyoderma gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance)
Rash
Therapeutic response decreased (less preventive response)
Thirst
Weight decreased
Activities of daily living impaired
Ear infection

60+:

Agitation (state of anxiety or nervous excitement)
Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)
Hyperventilation
Incoherent (talking in a confused and unclear way)
Pruritus generalised (generalized itching)
Reaction to azo-dyes
Tremor (trembling or shaking movements in one or more parts of your body)

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 8 people, 53.33%
Allergies: 8 people, 53.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 40.00%
Polyarthritis (arthritis which involves 5 or more joints simultaneously): 5 people, 33.33%
Menopausal Symptoms: 5 people, 33.33%
Juvenile Arthritis (arthritis-related condition that develops in children or teenagers): 5 people, 33.33%
Hypersensitivity: 1 person, 6.67%
High Blood Cholesterol: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Oracort and Pulmicort?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously